24 August 2022 : Clinical Research
Risk Factors and Pathogen Spectrum in Continuous Ambulatory Peritoneal Dialysis-Associated Peritonitis: A Single Center Retrospective Study
Supei Yin1ABCDEFG, Ming Tang1ABCDE, Zhengsheng Rao1ABCD, Ximing Chen1ABDE, Mengjuan Zhang1ABCDEFG, Ling Liu1ABCDE, Keqin Zhang1ABCDEFG*DOI: 10.12659/MSM.937112
Med Sci Monit 2022; 28:e937112
Table 4 Analysis of drug susceptibility and drug resistance rate of common bacteria with positive peritoneal fluid (%).
| Drug names | Escherichia coli | Staphylococcus epidermidis | Staphylococcus capitis | Serratia liquefaciens |
|---|---|---|---|---|
| Penicillin G | – | 100.00% | 94.42% | – |
| Ampicillin | 100.00% | 100.00% | 74.56% | – |
| Compound trimethoprim | 80.51% | 87.82% | 77.35% | – |
| Cefepime | 71.86% | 82.32% | 81.42% | 62.84% |
| Ceftiofur | 72.86% | 80.32% | 64.42% | 78.84% |
| Ceftriaxone | 62.12% | 84.58% | 79.56% | 56.61% |
| Ciprofloxacin | 45.64% | 71.52% | 54.03% | 61.28% |
| Norfloxacin | 79.86% | 67.56% | 76.16% | 65.28% |
| Ofloxacin | 87.86% | 78.06% | 80.86% | 70.67% |
| Amoxicillin-clavulanic acid | 41.96% | 47.46% | 36.26% | 55.38% |
| Amikacin | 37.16% | 32.77% | 36.14% | 33.47% |
| Piperacillin/tazobactam | 18.62% | 20.62% | 23.62% | 21.08% |
| Cefoperazone and sulbactam sodium | 29.52% | 30.70% | 29.31% | 28.75% |
| Meropenem | 6.74% | 10.60% | 4.65% | 2.23% |
| Imipenem | 2.23% | 6.25% | 4.44% | 4.44% |
| Ceftazidime | 10.53% | 20.47% | 19.27% | 11.08% |
| Linezolid | 0.00% | 0.00% | 0.00% | 0.00% |
| Teicoplanin | 0.00% | 0.00% | 0.00% | 0.00% |
| Levofloxacin | 0.00% | 0.00% | 0.00% | 0.00% |
| Vancomycin | 0.00% | 3.30% | 0.00% | 0.00% |
| Tigecycline | 0.00% | 0.00% | 0.00% | 0.00% |